What investment strategy does AdBio Partners focus on?

AdBio Partners focuses on VC strategies in the private equity space.

How many portfolio companies does AdBio Partners have?

AdBio Partners has 25 active portfolio companies and 2 completed exits and 2 funds tracked on GP Intel.

Where is AdBio Partners headquartered?

AdBio Partners is headquartered in Paris, France.

What is AdBio Partners's assets under management?

AdBio Partners manages approximately €133M in assets under management.

When was AdBio Partners founded?

AdBio Partners was founded in 2015.

What sectors does AdBio Partners invest in?

AdBio Partners invests across Healthcare.

What are AdBio Partners's recent exits?

Recent realized exits by AdBio Partners include: Agomab Therapeutics (2026) to Nasdaq (IPO); GAMUT Therapeutics (2021) to SparingVision.

Home/GPs/AdBio Partners

DetailCard

AdBio Partners

Paris, France·Founded 2015·

Venture Capital

·adbio.partners

AdBio partners, founded in 2016 and based in Paris, France, is a venture capital firm specializing in early-stage investments in promising life sciences startups across Europe. It focuses on building pioneering healthcare companies by partnering closely with scientific founders and academic institutions, providing both capital and entrepreneurial support.

AUM

€133M

Funds

vintages 2017–2021

Portfolio

Exits

AdBio Partners is a Paris venture capital firm with €133M AUM, 25 active companies and 2 exits.

SectorsHealthcare

Key takeaways

·Top sector focus: Biotech (93% of portfolio).
·Fund cadence: ~4Y between vintages · last raise 2021.

Sector breakdown

27 companies

Biotech

25 · 93%

MedTech

1 · 4%

Healthcare

1 · 4%

Geography breakdown

7 geographies

France

18 · 67%

Belgium

3 · 11%

Spain

2 · 7%

Denmark

1 · 4%

Ireland

1 · 4%

Germany

1 · 4%

Key facts

HQParis, France

Founded2015

Websiteadbio.partners

Recent exits

AdBio Partners took Agomab Therapeutics public in 2026 after 7 years.

AdBio Partners sold GAMUT Therapeutics to SparingVision in 2021 after 1 year.

Coverage notes

2 funds tracked, 27 portfolio companies (25 active · 2 realized). Verified weekly from public filings and deal announcements.

Funds & portfolio

Every fund AdBio Partners has raised, with its portfolio companies. Hand-checked from public filings.

2 funds

Fund

Strategy

Vintage

Size

Assets

Exits

AFB Fund II

VC2021€86M17 assets

2021 · 5yr

€86M

–

Unrealized

17 held

Company	Entry
AndzonBio1 Biotech · France	2024
AndzonBio2 Biotech · France	2025
Anoat Therapeutics Biotech · France	2023
Astraveus MedTech · France	2023
Augustine Therapeutics Biotech · Belgium	2019
Calida Therapeutics Biotech · France	2023
Cephagenix Biotech · Denmark	2025
Depth Charge Therapeutics Biotech · Ireland	2021
DiogenX Biotech · France	2020
EvlaBio Biotech · Germany	2025
Integra Therapeutics Biotech · France	2021
Kiji Therapeutics Biotech · France	2023
Orikine Bio Biotech · Spain	2026
Ribonexus Biotech · France	2021
Tenpoint Therapeutics Biotech · UK	2023
Thabor Therapeutics Biotech · France	2021
Univercells Biotech · Belgium	2022

AFB Seed-Fund

VC2017€47M8 assets2 exits

2017 · 9yr

€47M

Unrealized

8 held

Company	Entry
Alderaan Biotechnology Biotech · France	2020
ARTHEx Biotech Biotech · Spain	2020
Kalsiom Biotech · France	2020
SparingVision Biotech · France	2019
Tridek-One Biotech · France	2019
Urania Therapeutics Biotech · France	2019
Wellium Healthcare · France	2020
Yukin Therapeutics Biotech · France	2019

Realized

2 exits

Company	Entry	Exit	Type	Buyer	MOIC
Agomab Therapeutics Biotech · Belgium	2019	2026	IPO	Nasdaq (IPO)	–
GAMUT Therapeutics Biotech · France	2020	2021	Trade Sale	SparingVision	–

About AdBio Partners

AdBio partners is a French venture capital firm with €133 million of assets under management, founded in 2016 and headquartered in Paris. The firm specialises in early-stage investments in promising life sciences startups across Europe, focusing on building pioneering healthcare companies by partnering closely with scientific founders and management teams.

Investment thesis

AdBio Partners targets European life sciences startups at seed and Series A-B stages, with sector focus on biotech (drug discovery and development), MedTech and selective HealthTech verticals. Equity ticket sizes typically range from €1 million seed positions through to €10 million Series A-B follow-on commitments. The life sciences-exclusive mandate enables deep scientific and clinical expertise across portfolio companies, distinguishing AdBio from generalist VC peers.

Recent activity

Recent realised exits include Agomab Therapeutics (healthcare, 2026) and Univercells (biotech, 2024), reflecting active distribution across the life sciences portfolio. The platform tracks 2 funds, 20 active portfolio companies and 2 realised exits across the multi-vintage European life sciences programme.

Frequently asked questions

What investment strategy does AdBio Partners focus on?: AdBio Partners focuses on VC strategies in the private equity space.
How many portfolio companies does AdBio Partners have?: AdBio Partners has 25 active portfolio companies and 2 completed exits and 2 funds tracked on GP Intel.
Where is AdBio Partners headquartered?: AdBio Partners is headquartered in Paris, France.
What is AdBio Partners's assets under management?: AdBio Partners manages approximately €133M in assets under management.
When was AdBio Partners founded?: AdBio Partners was founded in 2015.
What sectors does AdBio Partners invest in?: AdBio Partners invests across Healthcare.
What are AdBio Partners's recent exits?: Recent realized exits by AdBio Partners include: Agomab Therapeutics (2026) to Nasdaq (IPO); GAMUT Therapeutics (2021) to SparingVision.